Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 6.28%
As of Wednesday, July 29, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 6.28%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Commentary & Analysis
Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 7.39%
As of Tuesday, July 28, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 7.39%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Up 6.23%
As of Monday, July 27, Kyverna Therapeutics, Inc.’s KYTX share price has surged by 6.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.07%
As of Monday, July 13, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 12.64%
As of Friday, July 10, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 12.64%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | KYTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $443.8 | $252.6 | 36% |
|
| Shares Out (Mil) | 60.4 | 52.3 | 52% |
|
| Institutional Ownership | 96.0% | 92.1% | 69% |
|
| Float (Mil) | 35.5 | 40.2 | 40% |
|
| Beta | 1.96 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 885 | 455 | 68% |
|
| Price Change (52-week) |
94.2% | 52.9% | 91% |
|
| Growth | KYTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.679) | ($2.877) | ($2.954) | |
| Month Ago EPS | ($0.679) | ($2.877) | ($2.954) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.744) | ($2.924) | ($2.848) | |
| Year/Year Chg | 3.3% | (21.1%) | 4.3% | |
| Financials | KYTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($156) | ($43) | 8% |
|
| EPS (TTM) | ($3.220) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($150) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $5 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $32 | $5 | 35% |
|
| Enterprise Value (Q1) (Mil) | $288 | $180 | 29% |
|
| Valuation | KYTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.26 | 2.56 | 55% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KYTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (60.4%) | (49.8%) | 10% |
|
| ROE | (74.5%) | (55.5%) | 12% |
|
| Liabilities to Assets | 23.9% | 30.3% | 16% |
|
| F-Score | 2 | 3 | 7% |
|
Kyverna Therapeutics, Inc. did not pass any screens on 7/31/2026.
